Skip to content
Peptide Atlas
All peptides

Imunofan

Tier 2 · Preclinical
Also known as Imunofan peptide · Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine

Strongest evidence is Tier 1: a randomized clinical trial in type 2 diabetics with diabetic foot syndrome5 and a human RCT using Imunofan as a vaccine adjuvant against bacterial challenge3, plus SPPS/RP-HPLC/LC-MS synthesis validation. However, most of the evidence base is lower tier: numerous human observational studies (largely Russian-language, developer-affiliated), animal and in vitro mechanistic work, and expert-opinion web sources. Key caveats: clinical literature lacks independent Western replication and is predominantly non-English; HIV and hepatitis B/C efficacy claims rest on single tier-3 web sources; specific mechanistic/PK figures (ceruloplasmin activity increase, glutathione rise, bioavailability, intranasal half-life) are expert opinion rather than measured human PK; and animal data reporting hyperalgesia contradict the uniformly benign safety profile claimed elsewhere.

Half-life
~1 h
Routes
Subcutaneous injection · Intramuscular injection · Intranasal spray · Rectal suppository · Subconjunctival / local (ophthalmic, animal studies)
Goals
Immune support and immunomodulation · Antioxidant / oxidative-stress reduction · Anti-infective adjunctive support (chronic viral/bacterial infections) · Vaccine adjuvant · Tissue repair and wound healing · Hepatoprotection · Oncology supportive care (adjunct to chemoradiotherapy)
Cost / mg
Not recorded

How it works

Imunofan is a small synthetic peptide modeled on a fragment of thymopoietin, a natural thymic hormone that guides the development and activity of immune T-cells. Rather than simply revving up the immune system, it is described as an immunomodulator that nudges abnormal immune parameters back toward balance — boosting defenses when they are weak and calming them when they are overactive. It is reported to act in three overlapping stages: within a few hours it activates the body's antioxidant defenses (scavenging reactive oxygen species and raising glutathione); over the following days to weeks it enhances the activity of immune cells such as neutrophils, macrophages, NK cells and B-cells; and over months it helps normalize the ratio of T-cell subtypes and consolidate immune memory. It is also credited with antioxidant and liver-protective actions and with stimulating tissue repair.

Overview

Overview

Imunofan (also known by its chemical name Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine, sequence RDKVYR) is a synthetic hexapeptide with the molecular formula C36H61N13O10 and a molecular weight of approximately 836 Da. It is modeled on positions 32-37 of thymopoietin, a 49-amino-acid thymic hormone; some sources instead describe the biologically active region as the pentapeptide fragment at positions 32-36 (Arg-Lys-Asp-Val-Tyr), or the 32-36 active site of thymopoietin II with an added N-terminal arginine residue.

The parent hormone thymopoietin binds membrane receptors on prothymocytes and mature T cells, coupling to adenylate cyclase in precursor cells and guanylate cyclase in mature T cells, thereby directing the differentiation and functional activation of T-lymphocyte subpopulations.

Reported Mechanism

Imunofan is described as acting through a three-phase temporal profile:

  • Fast phase (onset within 2-3 hours): antioxidant modulation. It is reported to modulate circulating ceruloplasmin and lactoferrin, activate the ceruloplasmin-transferrin antioxidant system (with a reported 30-40% increase in ceruloplasmin catalytic activity), enhance catalase and glutathione peroxidase, raise intracellular reduced glutathione 2-3 fold, scavenge reactive oxygen species, and inhibit lipid peroxidation.
  • Intermediate phase (reported variably as ~2-3 days or ~7-10 days): immune cell activation. Reported effects include enhanced neutrophil and macrophage bactericidal/phagocytic activity, enhanced NK cytotoxicity, B-cell differentiation and antibody production, increased IL-2 from T-helper cells, modulation of CD4/CD8 marker expression, normalization of IgA/IgG, stabilization of Th1/Th2 balance, and decreased TNF and IL-6.
  • Slow phase (up to 4 months): normalization of CD4/CD8 T-cell ratios and consolidation of immune memory.

Imunofan is characterized as modulatory/immunocorrective rather than simply stimulatory — reported to normalize abnormal immune parameters bidirectionally toward homeostasis, enhancing T-cell function and antibody production in immunosuppressed states while reducing excessive activation in hyperactivated states (autoimmunity, allergy). Additional reported actions include hepatic antioxidant defense activation, upregulation of cytochrome P450 and glutathione-S-transferase, epigenetic tissue-repair effects via DNA-demethylation gene activation, and a protein-kinase-C-dependent modulation of P-glycoprotein/multidrug-resistance transporters (in vitro).

Structural work (NMR in aqueous solution and molecular dynamics simulation) identified a predominant conformation stabilized by a salt bridge between the Asp2 side-chain oxygen and the Arg6 NH proton.

Regulatory Status and Uses

Imunofan was developed at the Institute of Immunology in Moscow during the 1980s-1990s and approved for clinical use in Russia in the 1990s. It is registered in Russia and several CIS countries (including for veterinary immunomodulation) for immunodeficiency states, chronic infections (hepatitis B and C, brucellosis, HPV, chlamydia, opportunistic infections), post-surgical recovery, oncology supportive therapy, and as a vaccine adjuvant. It is marketed as an immunostimulant/immunomodulator with antioxidant and hepatoprotective properties.

Imunofan has NOT received regulatory approval from the FDA, EMA, or MHRA.

Evidence Base

Imunofan has reportedly been studied in over 100-200 clinical publications, predominantly in Russian-language medical literature produced largely by or affiliated with its developer, without independent Western replication.

Higher-tier evidence includes a randomized clinical trial in type 2 diabetics with diabetic foot syndrome (which reported corrected immune dysfunction, reduced insulin resistance, improved clinical/laboratory parameters and normalized cellular and humoral immunity) and a controlled animal study in BALB/c mice using Imunofan as a vaccine adjuvant against an E. coli O157:H7 challenge (not a human trial). Notably, in that mouse study, ESI+Imunofan produced protection comparable to Freund's adjuvant (reduced bacterial shedding) but elicited a lower IgG response, suggesting a role in non-antibody-mediated immunity.

Human observational studies report benefits in advanced/toxic diphtheria (4.1- to 4.8-fold mortality reduction as an adjuvant), herpesvirus-associated optic neuritis, chronic suppurative otitis media, venous trophic ulcers in the elderly, and oncology supportive care (reduced radiation-induced complications and enhanced free-radical inactivation reserve). Claims regarding HIV (improved CD4+ counts, reduced viral load, delayed AIDS progression) and hepatitis B/C (improved liver function tests and reduced viral load in '1000+' patients) rest on single low-tier web sources and are not corroborated by higher-tier primary studies in the source set.

In vitro, Imunofan stimulated human fibroblast proliferation by 20-40% and keratinocyte proliferation by 20-50%, and induced genes involved in DNA demethylation and immune responses. Animal studies show moderate wound-repair promotion, restoration of gut-associated lymphoid tissue after cyclophosphamide immunosuppression, and stabilization of testicular immune homeostasis under environmental stress.

What the research shows

139 findings extracted from the 24 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 7 human trial findings, 27 human study findings, 8 animal findings, 3 in vitro findings and 5 expert opinion findings.

  • human trialESI+Imunofan showed comparable reduction in bacterial shedding to Freund's adjuvant (3.1 ± 0.4 log10 CFU/g vs. 2.9 ± 0.3)3

  • human trialESI+Imunofan elicited lower IgG response (9.1 ± 0.6 log10) compared to ESI+Freund's adjuvant (12.3 ± 0.8 log10)3

  • human trialImunofan potentiates the effect of basic therapy in type 2 diabetes mellitus patients with diabetic foot syndrome5

  • human trialImunofan corrects immune dysfunction in type 2 diabetes mellitus patients with diabetic foot syndrome5

  • human trialCombined treatment with imunofan reduced the magnitude of insulin resistance5

  • human trialImunofan caused positive clinical and laboratory parameters in T2DM patients5

  • human trialImunofan improved quality of life in T2DM patients5

  • human studyImunofan combined with local treatment increased leukocytes, lymphocytes and macrophages by day 7 of treatment2

Show 42 more findings

  • human studyComplex treatment with Imunofan (immune correction) and pulsed high-intensity optical irradiation contributes to conversion of chronic inflammation to acute inflammation with initiation of reparation processes and tissue regeneration2

  • human studyImunofan combined with myelopid corrects immune deficiency in patients with chronic suppurative otitis media post-sanation surgery4

  • human studyTreatment with imunofan and myelopid combination proved more efficacious than conventional antibacterial therapy alone in restoring T-helper counts4

  • human studyTreatment with imunofan and myelopid combination proved more efficacious than conventional antibacterial therapy alone in restoring B-lymphocyte counts4

  • human studyTreatment with imunofan and myelopid combination proved more efficacious than conventional antibacterial therapy alone in restoring phagocyte counts4

  • human studyImunofan and myelopid combination treatment reduces elevated T-suppressor levels in chronic suppurative otitis media patients4

  • human studyImunofan and myelopid combination treatment reduces elevated IgM levels in chronic suppurative otitis media patients4

  • human studyImmunofan is able to restore cell immunity, the oxygen-dependent neutrophilic bactericidal system and antiviral antibody production6

  • human studyIncluded into the complex therapy of patients with cancer diseases, Immunofan enhances the body's reserve capacity to inactivate free radicals and oxidants, substantially shortens radiation and toxic reactions6

  • human studyUsed in the complex therapy for chronic infections (brucellosis, hepatitis B and C, opportunistic infections), Immunofan enhances antiviral and antibacterial immunity, shortens the manifestation of clinical symptoms and major syndromes of diseases6

  • human studyImmunofan is able to restore cell immunity6

  • human studyImmunofan enhances antiviral antibody production6

  • human studyImmunofan enhances the body's reserve capacity to inactivate free radicals and oxidants in cancer patients6

  • human studyImmunofan substantially shortens radiation and toxic reactions in cancer therapy6

  • human studyImmunofan enhances antiviral and antibacterial immunity in chronic infections (brucellosis, hepatitis B and C, opportunistic infections)6

  • human studyImmunofan shortens the manifestation of clinical symptoms and major syndromes in chronic infectious diseases6

  • human studyImunofan reduced the occurrence of specific complications in advanced and toxic diphtheria7

  • human studyLethality fell 4.1-4.8-fold in patients with advanced and toxic diphtheria7

  • human studyImmunization with diphtheria toxoid (AD-M) resulted in changes of in vitro TNF and IL-6 production by peripheral blood mononuclear cells8

  • human studySerum levels of TNF were markedly increased over a period of 3 weeks following AD-M immunization8

  • human studyPostvaccinal cytokine production disturbances may be corrected by pretreatment with Imunofan (synthetic hexapeptide)8

  • human studyImmunofan and tactivin, employed as a means of immunological correction in the complex treatment of adenocarcinoma, decrease the onset frequency of radiation-induced complications19

  • human studyImmunofan shows tendency to normalization of HCT-test results19

  • human studyImmunofan somewhat exceeds tactivin in the efficacy of endometrium adenocarcinoma treatment19

  • human studyMultiple studies with >1000 patients combined demonstrate improved liver function tests, reduced viral load, and enhanced treatment response when imunofan is added to standard antiviral therapy for chronic hepatitis B/C21

  • human studySignificant reduction in ALT/AST levels and improvement in liver histology scores21

  • animalImunofan stimulates readaptation processes in the testes after use against the background of environmental immunosuppression12

  • animalImunofan administration following Cyclophosphamide-induced immunosuppression increases the length and width of aggregated lymphoid nodules in the small intestine by day 713

  • animalIn ear pinna injury model in mice, IM moderately promoted tissue repair (8% in BALB/c and 36% in C57BL/6 in comparison to control)14

  • animalIntramuscular administration of Imunofan produced hyperalgesia with decreases in thresholds of nociceptive reactions17

  • animalHyperalgesia in stress-sensitive rats was significantly greater than in stress-resistant animals following Imunofan administration17

  • animalIntramuscular injection of imunofan (0.01 ml, 0.005% solution) depressed active behaviour of animals in open field and reduced pain thresholds18

  • animalImunofan-induced hyperalgesia was much higher in non-resistant rats compared to resistant ones18

  • animalIntracerebroventricular injections of imunofan were accompanied by stronger and more complex changes of pain sensitivity18

  • in vitroImunofan (IM) exerted statistically significant pro-proliferative activity in skin cells9

  • in vitroImunofan (RDKVYR peptide) stimulates skin cell proliferation10

  • in vitroImunofan (RDKVYR peptide) stimulates skin cell proliferation14

  • expert opinionApproved peptide drugs undergo a rigorous path of development and approval, with extensive clinical trials often consisting of thousands of subjects to establish efficacy and safety20

  • expert opinionIn immunosuppressed patients, it enhances T-cell function and antibody production21

  • expert opinionIn hyperactivated immune states (autoimmunity, allergic disease), it has regulatory effects that reduce excessive immune activation21

  • expert opinionStudied in over 200 clinical publications in Russian-language medical literature21

  • expert opinionEnhances antibody response to vaccines by 2-4x21

How it works

Based on 3 human trial findings, 5 human study findings, 9 animal findings, 17 in vitro findings, 10 expert opinion findings and 5 theoretical findings.

  • human trialImunofan's protection despite weaker humoral responses suggests a unique role in modulating non-antibody-mediated immunity3

  • human trialImunofan is an immunoregulatory peptide5

  • human trialImunofan significantly normalizes cellular and humoral immunity5

  • human studyImmunofan decreases the levels of inflammatory mediators, such as TNF and IL-6, and activates the redox system6

  • human studyTNF release was suppressed but IL-6 production was stimulated following AD-M immunization8

  • human studyImmunofan exhibits a pronounced immunocorrector effect indicated by increasing level of lymphocytes (including CD3+, CD4+, CD8+, and CD19+)19

  • human studyImmunofan increases helper coefficient (CD4+/CD8+)19

  • human studyImmunofan increases phagocyte activity of neutrophils19

Show 41 more findings

  • animalImunofan stimulates the production of cytokines and hormones12

  • animalImunofan normalizes the function of immunocompetent cells12

  • animalImunofan stabilizes the immune homeostasis of the testes12

  • animalImunofan increases the height and width of lymphoid nodules and internodular zones as structural components of lymphoid formations in the small intestine13

  • animalImunofan has the ability to neutralize the effects of Cyclophosphamide13

  • animalImunofan regenerates damaged cells and helps maintain the population of lymphocytes13

  • animalIntramuscular administration of Imunofan suppressed active behavior of animals in open field test17

  • animalIntracerebroventricular administration of Imunofan was accompanied by more marked and complex changes in pain sensitivity compared to intramuscular administration17

  • animalImmune stimulation with imunofan influences pain responses depending on individual resistance of animals to stress18

  • in vitroRDKVYR peptide was found to induce significant transcriptional responses9

  • in vitroImunofan affects proliferation of 46BR.1N fibroblasts14

  • in vitroImunofan affects proliferation of HaCaT keratinocyte cell lines14

  • in vitroImunofan affects proliferation of adipose-derived stem cells (ASCs)14

  • in vitroImunofan affects immune cells activation14

  • in vitroIM exerted statistically significant pro-proliferative activity in human fibroblast cell lines (30-40% increase in proliferation)14

  • in vitroIM exerted statistically significant pro-proliferative activity in human keratinocyte cell lines (20-50% increase in proliferation)14

  • in vitroIM induced enhanced activity of genes involved in active DNA demethylation in fibroblasts14

  • in vitroIM induced activation of genes involved in immune responses, migration, and chemotaxis in adipose-derived stem cells14

  • in vitroImunofan peptide at concentrations 0.05, 0.25 μg/ml has antimicrobial characteristics against toxigenic C. difficile strain15

  • in vitroMoxifloxacin concentration 0-1.5 MIC stimulates C. difficile growth, regardless of the imunofan concentration15

  • in vitroMaximum growth inhibition for C. difficile was achieved with combined effects of imunofan at 1.5 μg/ml and moxifloxacin at 2.5 MIC15

  • in vitroHydrophilic hexapeptide Imunofan produces a modulatory effect on multiple drug resistance transport proteins depending on their functional activity16

  • in vitroThe hexapeptide inhibited multiple drug resistance proteins during substrate transport16

  • in vitroImunofan increased multiple drug resistance protein activity in the latent period16

  • in vitroBy the inhibition of multiple drug resistance, specific activity of Imunofan more than 1000-fold surpassed that of other substrate analogues16

  • in vitroRegulatory effect of this hexapeptide depends on protein kinase C16

  • expert opinionImmunofan is a hexapeptide Arg-alpha-Asp-Lys-Val-Tyr-Arg designed by chemically modifying the thymic hormone Thymopoietin in positions 32-376

  • expert opinionImmunofan is a hexapeptide Arg-alpha-Asp-Lys-Val-Tyr-Arg designed by chemically modifying thymic hormone Thymopoietin in positions 32-376

  • expert opinionImmunofan restores the oxygen-dependent neutrophilic bactericidal system6

  • expert opinionImmunofan decreases the levels of inflammatory mediators, such as TNF and IL-66

  • expert opinionImmunofan activates the redox system6

  • expert opinionPeptides are molecules composed of up to 40 to 50 amino acids20

  • expert opinionPeptides occupy a distinct biochemical and regulatory niche between small-molecule drugs (generally <500 Daltons) and large biological proteins (>5000 Daltons)20

  • expert opinionImunofan (RDKVYR) is a synthetic hexapeptide derived from the 32-36 active site of thymopoietin II with an additional N-terminal arginine residue21

  • expert opinionActs as an immunocorrector normalizing immune function toward homeostasis regardless of the direction of the imbalance21

  • expert opinionRapidly increases intracellular reduced glutathione (GSH) levels by 2-3x21

  • theoreticalEnzymatic degradation by proteases and rapid clearance by renal filtration are the major reasons for short half-life in therapeutic peptides and proteins11

  • theoreticalThe threshold of renal filtration is about 40-50 kDa; biopharmaceuticals with a molecular weight below 50 kDa are rapidly eliminated by kidney filtration11

  • theoreticalMolecules with a negative surface charge are eliminated less rapidly than neutral and positive molecules due to repulsion by the negatively charged polysaccharides on membranes in the glomerular filter11

  • theoreticalTwo most frequently used half-life extension methods are the reduction in the rate of renal clearance or the exploitation of the recycling mechanism of FcRn by binding to the albumin or IgG-Fc11

  • theoreticalImunofan structure obtained after 10 ns of MD simulation in water shows hydrogen bonds and salt bridges14

Dosing

Based on 1 human study finding and 3 expert opinion findings.

  • human studyA single intramuscular injection was given daily for 8-10 days7

  • expert opinionImmunofan is manufactured in ampoules containing 1 ml of 0.005% sterile solution for subcutaneous and intramuscular injections6

  • expert opinionImmunofan is manufactured in ampoules containing 1 ml of 0.005% sterile solution for subcutaneous and intramuscular injections6

  • expert opinionCommercially available in Russia as injectable solution (0.005% for SC/IM injection), nasal spray, and rectal suppositories21

How the body handles it

Based on 1 human trial finding, 3 in vitro findings, 1 expert opinion finding and 3 theoretical findings.

  • human trialImunofan (836 Da) was synthesized via SPPS, purified by RP-HPLC, and validated by LC-MS3

  • in vitroCD spectra of Imunofan peptide in PBS at pH 7.4 measured over temperature range 25-50°C14

  • in vitroIM displayed stability in aqueous solutions14

  • in vitroIn plasma, IM was rapidly bound by albumins14

  • expert opinionPharmacological phases occur over approximately 2-3 hours after administration21

  • theoreticalPeptides and proteins exhibit short plasma half-lives, typically from a few minutes to a few hours, leading to the necessity for frequent or continuous injections11

  • theoreticalThe growth hormone, with a molecular weight of 22 kDa, has a half-life of 0.36 h after intravenous injection and 3.4 h after subcutaneous injection11

  • theoreticalThe half-life of glucagon-like peptide-1 (GLP-1) is only 1-2 min, because of inactivation by dipeptidyl peptidase-4 (DPP-4)11

Safety and side effects

Based on 4 in vitro findings and 3 expert opinion findings.

  • in vitroImunofan revealed no cytotoxicity over a vast range of concentrations9

  • in vitroImunofan had no allergic properties9

  • in vitroIM revealed no cytotoxicity over a vast range of concentrations14

  • in vitroIM had no allergic properties14

  • expert opinionUnapproved peptides are frequently carrying disclaimers like research chemical or not for human consumption to circumvent regulatory oversight20

  • expert opinionPeptides produced on the gray market are not subject to Good Manufacturing Practice (cGMP) guidelines or regulatory oversight20

  • expert opinionNo significant adverse effects reported across extensive clinical use21

What people use it for

Based on 2 human trial findings, 6 human study findings, 1 animal finding, 3 in vitro findings, 6 expert opinion findings and 1 theoretical finding.

  • human trialImunofan is a synthetic peptide adjuvant3

  • human trialImunofan can serve as a safer alternative to conventional adjuvants3

  • human studyImunofan was used for immune correction in elderly and senile patients with venous trophic ulcers2

  • human studyImmunofan use ensures the continuum of chemoradiotherapy6

  • human studyImmunofan ensures the continuum of chemoradiotherapy6

  • human studyImunofan was used as adjuvant to conventional treatment in diphtheria7

  • human studyImunofan is recommended for patients with allergic reaction to diphtheria antitoxin7

  • human studyImunofan treatment could prevent some postvaccinal complications8

Show 11 more findings

  • animalImunofan is an immune stimulator17

  • in vitroRDKVYR is a synthetic hexapeptide assessed for potential efficacy in stimulation of tissue repair and wound healing10

  • in vitroImunofan promotes tissue repair10

  • in vitroImunofan promotes tissue repair14

  • expert opinionImunofan-RDKVYR Peptide is a potential agent in regenerative medicine13

  • expert opinionA parallel and pervasive gray market has emerged, driven by direct-to-consumer sales of unapproved peptides20

  • expert opinionUnapproved peptides are aggressively marketed to the general public through social media and online forums20

  • expert opinionPurported benefits of unapproved peptides include accelerated musculoskeletal injury recovery, muscle hypertrophy, and athletic performance enhancement20

  • expert opinionApproved in Russia and several CIS countries as an immunomodulatory, hepatoprotective, and antioxidant therapeutic agent21

  • expert opinionUsed clinically for chronic infections (hepatitis B/C, HPV, chlamydia), immunodeficiencies, post-surgical recovery, oncology adjunctive therapy, and as a vaccine adjuvant21

  • theoreticalImunofan (RDKVYR hexapeptide) is marketed as an immunostimulant14

Other findings

Based on 2 expert opinion findings.

  • expert opinionGlobal sales of approved peptide drugs will likely reach $75 billion USD by 202820

  • expert opinionDeveloped at the Institute of Immunology in Moscow during the 1980s-1990s21

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Most clinical evidence is Russian-language and from the developer, without independent Western replication.

Imunofan: Mechanism, Dosing & Research — PeptideSciences101 notes that published clinical evidence for Imunofan is predominantly from Russian-language literature produced largely by or affiliated with its developer, that independent replication by Western research groups is absent, and that most primary sources are not indexed in English-language databases. Imunofan: Research Profile, Mechanism & Protocols | PepGuide | PepGuide and Imunofan - Wikipep — The Peptide Encyclopedia cite 'over 100' and 'over 200' clinical publications almost entirely in Russian literature.

Single source

HIV and hepatitis B/C efficacy claims rest on single low-tier web sources.

Claims that Imunofan improves CD4+ counts, reduces viral load and delays AIDS progression come only from tier-3 Imunofan: Research Profile, Mechanism & Protocols | PepGuide | PepGuide, and the '1000+ patient' hepatitis benefit only from tier-3 Imunofan - Wikipep — The Peptide Encyclopedia; neither is corroborated by higher-tier primary studies in the source set.

Contested

Rat studies report that Imunofan lowered pain thresholds, unlike the uniformly benign safety profile presented in consumer-facing summaries.

Two rat studies—[Nociceptive reactions during stimulation of immunity in rats with various individual resistance to stress] and Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress—found that intramuscular and intracerebroventricular Imunofan (0.005% solution) suppressed active behavior in the open-field test and produced hyperalgesia (reduced thresholds of nociceptive reactions), with the effect significantly greater in stress-sensitive animals than in stress-resistant ones. This behavioral/nociceptive effect is not reflected in the 'no significant adverse effects reported across extensive clinical use' statement in Imunofan - Wikipep, nor in the finding that the peptide showed no cytotoxicity and no allergic properties in human skin-cell cultures.

Limited evidence

Many mechanistic and pharmacokinetic details are expert-opinion or in vitro, not confirmed in humans.

Specific figures such as 30-40% ceruloplasmin activity increase, 2-3x glutathione rise, 2-4x vaccine antibody enhancement, ~90-95% subcutaneous bioavailability, and 2-4 hour intranasal half-life derive from tier-3 web sources (Imunofan: Research Profile, Mechanism & Protocols | PepGuide | PepGuide, Imunofan - Wikipep — The Peptide Encyclopedia, Imunofan Dosing, Need to Know Information, Safety,… | Peptide Initiative) as expert opinion rather than measured human pharmacokinetic studies.

Single source

Adjuvant study reports weaker antibody response than a standard adjuvant.

Solid-Phase Synthesized Imunofan Confers Clinically Relevant Protection using a Chimeric Protein Vaccine Candidate Against E. coli O157:H7 in BALB/c Mice. (tier-1) found ESI+Imunofan elicited a substantially lower IgG response than ESI+Freund's adjuvant (9.1 vs 12.3 log10) despite comparable protection, tempering claims of enhanced antibody production seen in other sources.

Other

Imunofan is not approved by major Western regulators and much online marketing is unregulated.

Immunofan (Arginyl-Alpha-Aspartyl-Lysyl-Valyl-Tyrosyl-Arginine): Research Evidence & Safety Profile | PeptideInsight states Imunofan has no FDA, EMA, or MHRA approval, and Safety and Efficacy of Approved and Unapproved Peptide Therapies for ... describes a pervasive gray market of unapproved peptides sold without cGMP or regulatory oversight, relevant to product quality and claims.

Using it with other compounds

Check a stack
  • ThymulinSame mechanism

    Worth caution

    Both are thymus-derived peptide hormones that normalize T-cell maturation, CD4/CD8 balance and NK cytotoxicity while dampening pro-inflammatory cytokines. Because they converge on the same thymic immune-tuning output, running them together is largely redundant rather than additive — pick one thymic immunomodulator rather than stacking two.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although both peptides influence T-cell maturation, CD4/CD8 balance, NK activity and cytokine levels, they act through different molecular routes: Imunofan signals via thymopoietin receptors and cyclase/PKC pathways, whereas Thymulin depends on zinc-activated peptide, NF-κB/p38 MAPK inhibition and α7-nicotinic receptors. Shared functional endpoints do not establish that the two work through the same mechanism or that combining them is redundant.

    Shares innate immune · anti inflammatory · T cell regulation

  • VilonSame downstream effect

    Worth caution

    Vilon is a Khavinson bioregulator that improves CD4/CD8 ratio, stimulates thymic/immune cell differentiation and suppresses TNF/IL-6, reaching the same immune-normalizing endpoint as imunofan but via a proposed gene/chromatin route rather than thymopoietin receptors. Overlapping goals mean modest additive value at best and heavy redundancy in immune correction.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation

  • PidotimodSame downstream effect

    Worth caution

    Pidotimod drives dendritic-cell maturation, Th1 differentiation, immunoglobulin production and phagocytosis through TLR2/TLR7 — a different upstream trigger than imunofan's thymopoietin pathway, but both raise T-cell competence and antimicrobial defense. They can complement each other for immune support, though effects on the same output should be monitored to avoid over-stimulation.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation

  • SelankComplementary

    No documented conflict

    Selank (a tuftsin analog) has immunomodulatory and Th1/Th2-balancing, anti-inflammatory effects alongside its main anxiolytic/nootropic role. Its immune actions run parallel to imunofan's without sharing the same receptor, so the two could complement each other where mild immune modulation plus CNS support is the goal.

    Tier 4Theoretical — not established

    Shares anti inflammatory · T cell regulation

  • KPVComplementary

    No documented conflict

    KPV is a potent NF-κB-suppressing anti-inflammatory (lowering TNF-α, IL-1β, IL-6) with mucosal/antimicrobial activity, working through a different mechanism than imunofan's thymic immunocorrection. Both push toward calmer inflammation and better mucosal defense, making them a plausible complementary anti-inflammatory pairing.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • LactoferrinComplementary

    No documented conflict

    Lactoferrin adds broad-spectrum antimicrobial and iron-homeostasis activity plus immune/antioxidant modulation. Its mechanisms differ from imunofan's thymic pathway, so combining innate antimicrobial defense with imunofan's enhanced phagocytic and NK activity is a reasonable complementary immune-support pairing.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · antimicrobial

  • TB-500Complementary

    No documented conflict

    TB-500 drives cytoskeletal-based cell migration, angiogenesis and NF-κB-suppressing anti-inflammatory repair. This converges with imunofan's reported fibroblast/keratinocyte stimulation and anti-inflammatory cytokine modulation through an entirely different mechanism, supporting a complementary tissue-recovery goal.

    Tier 4Theoretical — not established

    Shares tissue repair · anti inflammatory

  • LL-37Complementary

    No documented conflict

    Imunofan bidirectionally normalizes immune function, boosts phagocytosis/NK activity and antioxidant defenses, and supports tissue repair, while LL-37 adds direct antimicrobial and TLR-based innate actions. Different mechanisms converging on immune balance and repair.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · tissue repair

  • ThymalinSame mechanism

    Worth caution

    Imunofan is built on a thymopoietin fragment and acts as a bidirectional thymic-type immunomodulator — normalizing CD4/CD8 ratios, enhancing phagocytosis/NK activity, and reducing TNF/IL-6. That overlaps heavily with Thymalin's thymic T-cell restoration, so the two are largely doing the same job through the same thymic-hormone logic. Combining them adds little beyond either alone.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although both peptides normalize T-cell balance, modulate cytokines, and enhance phagocytosis, they do not do so through the same molecular route. Thymalin acts via DNA/histone binding and NF-kB-linked gene regulation, whereas Imunofan signals through thymopoietin membrane receptors, cAMP/PKA, and redox pathways—so their overlapping effects are convergent, not evidence of a shared mechanism.

    Shares innate immune · anti inflammatory · T cell regulation

  • Thymosin Alpha-1Same mechanism

    Worth caution

    Imunofan is a thymopoietin-fragment immunocorrector that normalizes T-cell ratios, boosts phagocyte and NK function, and modulates the Th1/Th2 cytokine balance — the same homeostatic immune-restoration role Thymosin Alpha-1 plays. Stacking two thymic-type immunomodulators is redundant; choose one based on the goal.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although both peptides influence T-cell function and Th1/Th2 balance, they act through distinct receptor systems and signaling cascades: Thymosin Alpha-1 works via Toll-like receptors (TLR2/3/4/7/9) and MHC Class I through IRF3, NF-κB and MyD88 pathways, whereas Imunofan acts on thymopoietin receptors and P-glycoprotein via adenylate cyclase, guanylate cyclase and PKC. A shared immune-restoring outcome does not mean they share a mechanism or are interchangeable.

    Shares innate immune · anti inflammatory · T cell regulation

  • ElafinComplementary

    No documented conflict

    Imunofan is a thymopoietin-based immunomodulator that boosts phagocytic/antimicrobial defenses and supports tissue repair, complementing elafin's antiprotease and antimicrobial actions. Different mechanisms supporting immune balance and mucosal repair.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · tissue repair

Safety and side effects

Safety Profile

Across extensive clinical use, no significant adverse effects have been reported according to developer-affiliated sources. In vitro studies found Imunofan produced no cytotoxicity over a wide concentration range, no basophil activation across seven independent experiments, and no allergic properties. An ophthalmic toxicity assessment in 30 Wistar rats (60 eyes) observed no toxic effects on intact tissue. Positive outcomes (cytokine and microbiota normalization) were reported in 42 frequently ill children with acute respiratory disease without documented adverse effects.

Important Caveats

  • Contradictory animal safety signal: In contrast to the uniformly benign profile claimed elsewhere, rat studies found that intramuscular Imunofan suppressed active behavior in the open field and produced hyperalgesia (reduced pain thresholds), with effects significantly greater in stress-sensitive/non-resistant animals; intracerebroventricular injection caused stronger and more complex changes in pain sensitivity. This adverse behavioral/nociceptive effect is not reflected in the 'no significant adverse effects' claims.
  • Evidence limitations: The safety record derives largely from Russian-language, developer-affiliated literature without independent Western replication.
  • No Western regulatory approval: Imunofan is not approved by the FDA, EMA, or MHRA.
  • Gray-market quality concerns: Unapproved peptides sold on the gray market are frequently labeled 'research chemical' or 'not for human consumption,' are marketed via social media, and are not subject to cGMP or regulatory oversight — raising concerns about product identity, purity, and quality.

This profile summarizes what the research reports and is not medical advice.

Reconstitution and handling

Pharmaceutical Forms

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

In Russia, Imunofan is available in three pharmaceutical forms:

  • Injectable solution: 0.005% (approximately 45 mcg/mL), for subcutaneous or intramuscular injection, manufactured in ampoules containing 1 mL of sterile solution.
  • Intranasal spray: 50 mcg per dose.
  • Rectal suppositories: 90-100 mcg per suppository.

Dosing (as reported)

Per the Russian pharmacopeia, the standard injectable single subcutaneous dose is 45 mcg (maximum daily dose 45 mcg), typically administered as a course of 5-15 injections over about 10-30 days.

In the clinical literature, adjuvant regimens have used, for example, 1 mL of 0.005% solution (~45 mcg) intramuscularly once daily for 8-10 days (advanced/toxic diphtheria), and 50 mcg intramuscularly daily for 10 days (herpesvirus-associated optic neuritis).

Preparation and Stability Notes

Imunofan is supplied as a ready-to-use sterile aqueous solution in ampoules rather than as a lyophilized powder requiring reconstitution. The peptide is reported to be stable in aqueous solutions. Structural characterization used circular dichroism spectra measured in PBS at pH 7.4 across 25-50°C. For research synthesis, Imunofan has been produced via solid-phase peptide synthesis (SPPS), purified by RP-HPLC, and validated by LC-MS.

Pharmacokinetically, Imunofan binds albumin and becomes undetectable in plasma within approximately one hour at 37°C, consistent with the short plasma half-lives typical of small therapeutic peptides. A separate expert-opinion source reports an intranasal half-life of ~2-4 hours and subcutaneous bioavailability of ~90-95%, though these figures are not confirmed by measured human pharmacokinetic studies.

Dosing information is reported from published sources and regulatory registration in Russia; it is not a recommendation. Imunofan is not approved by Western regulators.

Sources

Ordered by evidence quality — the strongest first.

  1. A first-in-human Phase I dose-escalation trial of the novel ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  2. [Effectiveness of local treatment of venous trophic ulcers in gerontological patients].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  3. Solid-Phase Synthesized Imunofan Confers Clinically Relevant Protection using a Chimeric Protein Vaccine Candidate Against E. coli O157:H7 in BALB/c Mice.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  4. [Peculiarities of the treatment of patients presenting with chronic suppurative otitis media associated with Gram-negative microorganisms].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  5. [Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2009
  6. [Imunofan: new-generation synthetic peptide agent].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1999
  7. [A trial of the use of the immunocorrective preparation Imunofan for treating diphtheria].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1996
  8. Changes in TNF and IL-6 production after diphtheria toxoid vaccination: drug modulation of the cytokine levels.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1996
  9. [PDF] Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair | Semantic Scholar(opens in a new tab)
    Tier 2Web · semanticscholar.org
  10. Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  11. recent-advances-in-half-life-extension-strategies-for- ...(opens in a new tab)
    Tier 2Web · scispace.com
  12. EFFECT OF IMUNOFAN INFLUENCE ON THE STRUCTURE OF THE TESTES, HORMONAL AND CYTOKINE PROFILE OF IMMATURE EXPERIMENTAL ANIMALS.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  13. Evaluation of Morphological and Histological Changes of Aggregated Lymph Nodes in the Small Intestine after Imofan Treatment in Immunosuppressed Rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  14. Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation and Promotes Tissue Repair(opens in a new tab)
    Tier 2Web · mdpi.com · 2020
  15. [Peptide imunofan and moxifloxacin combined effects on toxigenic strain Clostridium difficile in vitro.].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  16. Hydrophilic hexapeptide Imunofan as a hyperactive regulator of transport proteins for multiple drug resistance.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  17. Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  18. [Nociceptive reactions during stimulation of immunity in rats with various individual resistance to stress].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  19. [Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2001
  20. Safety and Efficacy of Approved and Unapproved Peptide Therapies for ...(opens in a new tab)
    Tier 3Web · preprints.org
  21. Imunofan - Wikipep — The Peptide Encyclopedia(opens in a new tab)
    Tier 3Web · wikipep.org · 2026
  22. (PDF) Recent Advances in Half-life Extension Strategies for ...(opens in a new tab)
    Tier 4Web · researchgate.net
  23. Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?(opens in a new tab)
    Tier 4Web · mdpi.com
  24. Imunofan-RDKVYR Peptide-Stimulates Skin Cell Proliferation and Promotes Tissue Repair. | Read by QxMD(opens in a new tab)
    Tier 4Web · read.qxmd.com

See something wrong or out of date on this page? Report it.